Study links Actos with delayed dementia
Diabetes medication Actos could be repurposed for Alzheimer's disease. Reuters reports that a clinical trial indicates that the “cheap generic treatment” appears to be associated with delayed onset of the memory-eating disease.
Reuters notes that earlier studies indicated this may be a potential benefit, but this latest trial was a heftier effort, based on German healthcare data from 2004 through 2010 across a data set that included 146,000 patients ages 60 and older who did not initially show signs of dementia.
Researchers found that 13,841 patients eventually suffered dementia but the risk was reduced for every three months patients took Actos.